News

Home>News
Apr 12 2021

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Covid-19 Inflammatory Cytokine Storm Treatment

By |2021-04-11T20:02:28-04:00April 12th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Jackson Center, PA, April 12, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Covid-19 Inflammatory Cytokine Storm Treatment.”  The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously. William A. Hartman, Chairman, ...

Apr 6 2021

Halberd Corporation CEO Letter

By |2021-04-05T20:46:11-04:00April 6th, 2021|Featured, Investor News, News|0 Comments

Q1-21 Accomplishments and Q2 Plans Jackson Center, PA, April 6, 2021 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC-PINK: HALB) It has been a very busy and fruitful first quarter of 2021.  Often, people get so wrapped up in the day-to-day events that we lose sight of just how far we have traveled.  ...

Mar 30 2021

Halberd Corporation’s Scientific Breakthrough: Conjugating Metallic Particles to SARS-CoV-2 and E. Coli Antigens

By |2021-03-29T20:24:19-04:00March 30th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Paves Way for Disease Elimination by Radio Frequency Waves Jackson Center, PA, March 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated (joined) metallic nanoparticles with its patent-pending SARS-CoV-2 antibody, while still maintaining the antibody’s antigen-neutralizing properties.  This was a key scientific hurdle to overcome in implementing its patent-pending extracorporeal disease eradication methodology through ...

Mar 23 2021

Halberd Corporation Completes Compilation of Medical Articles in Support of Nutraceuticals in Their VITA-SHIELD-MAX(TM) Immune Booster

By |2021-03-22T20:57:07-04:00March 23rd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 23, 2021 – Halberd Corporation (OTC-PINK: "HALB") has compiled a number of third party published articles from various medical publications which support the selection of the various nutraceuticals in Halberd’s VITA-SHIELD-MAXTM Immune Booster. William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, “After reviewing numerous peer reviewed articles from ...

Mar 18 2021

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application Covering Extracorporeal Treatment of COVID-19 and Other Medical Maladies

By |2021-03-17T21:09:58-04:00March 18th, 2021|Featured, Investor News, News|2 Comments

Jackson Center, PA, March 18, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Method for Treating and Curing Covid-19 Infection.”  The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously. William A. ...

Mar 16 2021

Halberd Corporation Starts VITA-SHIELD-MAX(TM) Immunity Boosting Nutraceutical Production

By |2021-03-15T18:53:11-04:00March 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 16, 2021 – Halberd Corporation (OTC PINK:HALB) has contracted with a major nutraceutical manufacturer to produce its initial production lot of Halberd’s VITA-SHIELD-MAXTM Immune Booster.  Halberd’s scientists designed this proprietary combination of vitamins and minerals to help the body increase its natural immunity and promote general health. Dr. Patricio Reyes, Halberd ...

Mar 11 2021

Halberd Corporation Files VITA-SHIELD-MAX(TM) Trademark For Immunity Boosting Nutraceutical

By |2021-03-10T19:37:28-05:00March 11th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 11, 2021 – Halberd Corporation (OTC PINK:HALB) has filed for trademark protection for the name VITA-SHIELD-MAXTM for its proprietary blend of over-the-counter nutraceuticals designed to boost the body’s immunity and generally enhance health. William A. Hartman, Chairman, President & CEO of Halberd Corp., stated, “We are pleased to be able to ...

Mar 9 2021

Halberd Corporation’s CEO Interviewed on “The Stock Day Podcast” – Focus on Halberd’s New 20x Affinity Neutralizing SARS-COV-2 Antibody

By |2021-03-08T20:35:16-05:00March 9th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 9, 2021 – Halberd Corporation’s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on The Stock Day Podcast, hosted by Everett Jolly.  In the interview, Mr. Hartman reviewed the company’s progress in developing SARS-CoV-2 spike protein antibodies and how they can be combined with other Halberd technologies ...

Mar 2 2021

Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater

By |2021-03-01T20:05:18-05:00March 2nd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 2, 2021 – Halberd Corp. (OTC PINK:HALB) has recently produced a proprietary monoclonal antibody that has at least 20 times greater neutralizing affinity than their original antibody against the SARS-COV 2 Spike protein. Dr. Reyes, Halberd’s Chief Technical Officer, indicated, “Our latest results indicate increased specificity of our second antibody, which ...

Feb 16 2021

Halberd Collaborates With GreenBioAZ, Inc. For the Development of Its Patent Pending Radio Frequency Technology to Eliminate Disease Pathogens

By |2021-02-15T21:23:39-05:00February 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, February 16, 2021 – Halberd Corp. (OTC PINK:HALB) has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease pathogens.  The methodology entails treating bodily fluids with an Antibody-Metallic Moiety Conjugate (AMMC) which targets a specific pathogen such as SARS-CoV-2 during extracorporeally ...

Go to Top